Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Ocvirk · SciRah

Researcher profile · Semantic Scholar

J. Ocvirk

Share profile

J. Ocvirk — researcher profile on SciRah

h-index: 20
Works: 119
Citations: 1,870

Most-cited papers

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
D. Cunningham, I. Láng, E. Marcuello, V. Lorusso +7 more
2013The Lancet Oncology614 citations
Semantic Scholar
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
J. Ocvirk, T. Brodowicz, F. Wrba, T. Ciuleanu +16 more
2010World Journal of Gastroenterology117 citations Open access
Semantic Scholar
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study
V. Velenik, J. Ocvirk, M. Mušič, M. Bračko +6 more
2011Radiation Oncology97 citations Open access
Semantic Scholar
Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
R. Hofheinz, G. Deplanque, Y. Komatsu, Y. Kobayashi +6 more
2016The Oncologist88 citations Open access
Semantic Scholar
A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis
J. Ocvirk, S. Heeger, P. McCloud, R. Hofheinz
2013Radiology and Oncology62 citations Open access
Semantic Scholar
A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
V. Velenik, J. Ocvirk, I. Oblak, F. Anderluh
2010European Journal of Surgical Oncology60 citations
Semantic Scholar
Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer
J. Ocvirk, S. Cencelj
2010Journal of the European Academy of Dermatology and Venereology55 citations
Semantic Scholar
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
L. K. Sekulovic, J. Guo, S. Agarwala, A. Hauschild +34 more
2018European Journal of Cancer49 citations Open access
Semantic Scholar
Metabolic Impact of Anti-Angiogenic Agents on U87 Glioma Cells
T. Mesti, P. Savarin, M. Triba, L. Le Moyec +3 more
2014PLoS ONE44 citations Open access
Semantic Scholar
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
L. K. Sekulovic, K. Peris, A. Hauschild, A. Stratigos +33 more
2017European Journal of Cancer39 citations Open access
Semantic Scholar
Malignant gliomas: old and new systemic treatment approaches
T. Mesti, J. Ocvirk
2016Radiology and Oncology34 citations Open access
Semantic Scholar
Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX).
D. Cunningham, I. Láng, V. Lorusso, J. Ocvirk +6 more
201333 citations
Semantic Scholar
EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity
R. Hofheinz, S. Lorenzen, J. Trojan, J. Ocvirk +12 more
2018Annals of Oncology30 citations Open access
Semantic Scholar
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials
D. Modest, T. Brodowicz, S. Stintzing, A. Jung +9 more
2012Oncology29 citations
Semantic Scholar
Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
T. Mesti, Cvetka Grašič Kuhar, J. Ocvirk
2023Biomedicines28 citations Open access
Semantic Scholar
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib
Ana Uršula Gavrić, J. Ocvirk, P. Mekjavić
2018Radiology and Oncology27 citations Open access
Semantic Scholar
Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
T. Mesti, M. E. Moltara, M. Boc, M. Reberšek +1 more
2015Radiology and Oncology22 citations Open access
Semantic Scholar
Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
J. Ocvirk, M. Reberšek, E. Škof, Z. Hlebanja +1 more
2012American Journal of Clinical Oncology21 citations
Semantic Scholar
Advances in the treatment of metastatic colorectal carcinoma
J. Ocvirk
200920 citations Open access
Semantic Scholar
Cetuximab in preoperative treatment of rectal cancer – term outcome of the XERT trial
V. Velenik, J. Ocvirk, I. Oblak, F. Anderluh
2012Radiology and Oncology19 citations Open access
Semantic Scholar
Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream
J. Ocvirk
2010Radiology and Oncology19 citations Open access
Semantic Scholar
Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis
M. Reberšek, M. Boc, Petra Cerkovnik, J. Benedik +4 more
2011Radiology and Oncology18 citations Open access
Semantic Scholar
KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
Alenka Ličar, Petra Cerkovnik, J. Ocvirk, S. Novaković
2010International Journal of Oncology18 citations Open access
Semantic Scholar
Retrospective Analysis of Treatment-naive Slovenian Patients with Metastatic Melanoma Treated with Pembrolizumab – Real-world Experience
N. Hribernik, M. Boc, J. Ocvirk, Jasna Knez-Arbeiter +3 more
2020Radiology and Oncology16 citations Open access
Semantic Scholar
Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients
P. Kopač, A. Koren, U. Bidovec-Stojkovič, M. Košnik +5 more
2024Diagnostics12 citations Open access
Semantic Scholar
Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream.
J. Ocvirk, M. Reberšek
2009Journal of Clinical Oncology12 citations
Semantic Scholar
The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer
I. Oblak, V. Velenik, F. Anderluh, B. Možina +1 more
2013Radiology and Oncology10 citations Open access
Semantic Scholar
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
J. Ocvirk, M. Reberšek, M. Boc
2011Anticancer Research10 citations
Semantic Scholar
Prevalence of BRAF, NRAS and c-KIT Mutations in Slovenian Patients with Advanced Melanoma
M. E. Moltara, S. Novaković, M. Boc, Marina Bučić +3 more
2018Radiology and Oncology9 citations Open access
Semantic Scholar
Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC).
J. Ocvirk, M. Reberšek, M. Boc, T. Mesti +1 more
20109 citations
Semantic Scholar
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
T. Mesti, Maša Sever, J. Ocvirk
2022Dermatology7 citations Open access
Semantic Scholar
Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients
M. Reberšek, T. Mesti, M. Boc, J. Ocvirk
2019Radiology and Oncology7 citations Open access
Semantic Scholar
Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
M. Gaiser, S. Lorenzen, K. Merx, J. Trojan +13 more
2019Cancer Medicine7 citations Open access
Semantic Scholar
Current management of chemotherapy-induced anemia with darbepoetin alfa: The APRIORI study.
N. Bittner, A. Cipkova, H. Móciková, E. Wojciechowska-Lampka +2 more
2011Journal of Clinical Oncology7 citations
Semantic Scholar
Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes
T. Mesti, Vid Ceplak Mencin, Biljana Mileva-Boshkoska, J. Ocvirk
2021Radiology and Oncology6 citations Open access
Semantic Scholar
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L. K. Sekulovic, K. Peris, A. Stratigos, A. Hauschild +28 more
2020Journal of the European Academy of Dermatology and Venereology6 citations Open access
Semantic Scholar
Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III
I. Oblak, F. Anderluh, V. Velenik, B. Možina +3 more
2011Radiology and Oncology6 citations Open access
Semantic Scholar
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.
L. Kandolf, P. Ascierto, L. Bastholt, I. Gavrilova +27 more
2024European Journal of Cancer5 citations Open access
Semantic Scholar
The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1st Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018
T. Mesti, M. Reberšek, J. Ocvirk
2023Radiology and Oncology5 citations Open access
Semantic Scholar
Nuclear Magnetic Resonance Metabolic Fingerprint of Bevacizumab in Mutant IDH1 Glioma Cells
T. Mesti, N. Bouchemal, C. Banissi, M. Triba +6 more
2018Radiology and Oncology5 citations Open access
Semantic Scholar
Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanoma
J. Ocvirk, M. Boc, M. Reberšek, T. Roš
20095 citations Open access
Semantic Scholar
Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial.
I. Koza, F. Wrba, Damir Vrbanec, J. Ocvirk +6 more
2009Journal of Clinical Oncology5 citations
Semantic Scholar
Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report
P. Kiraly, Alenka Lavrič Groznik, N. Valentinčič, P. Mekjavić +3 more
2022World Journal of Clinical Cases4 citations Open access
Semantic Scholar
Patients with metastatic melanoma treated with vemurafenib as monotherapy or in combination with cobimetinib.
J. Ocvirk, M. Reberšek, M. Boc, T. Mesti
20174 citations
Semantic Scholar
Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
J. Ocvirk, M. E. Moltara, T. Mesti, M. Boc +4 more
2016Radiology and Oncology4 citations Open access
Semantic Scholar
The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
T. Mesti, B. Boshkoska, Mitja Kos, Metka Tekavčič +1 more
2015Radiology and Oncology4 citations Open access
Semantic Scholar
Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.
M. Saunders, I. Láng, E. Marcuello, V. Lorusso +7 more
20133 citations
Semantic Scholar
Neoadjuvant bevacizumab, capecitabine, and radiotherapy in locally advanced rectal cancer: Interim results of a phase II CRAB trial.
V. Velenik, J. Ocvirk, M. Omejc, M. Mušič +5 more
20103 citations
Semantic Scholar
Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases
Maja Sljivic, Maša Sever, J. Ocvirk, T. Mesti +2 more
2024Radiology and Oncology2 citations Open access
Semantic Scholar
The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
A. Erman, M. Ignjatović, K. Leskovšek, S. Miceska +8 more
2023Biomedicines2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Mesti×18
Invite
T. Mesti — researcher profile on SciRah
M. Reberšek×13
Invite
M. Reberšek — researcher profile on SciRah
M. Boc×11
Invite
M. Boc — researcher profile on SciRah
V. Velenik×6
Invite
V. Velenik — researcher profile on SciRah

×6

Invite

F. Anderluh — researcher profile on SciRah

Invite

I. Oblak — researcher profile on SciRah

Invite

R. Hofheinz — researcher profile on SciRah

Invite

C. Hoeller — researcher profile on SciRah

Invite

L. Bastholt — researcher profile on SciRah

Invite

R. Vieira — researcher profile on SciRah

Invite

K. Putnik — researcher profile on SciRah

D. Cunningham×3

Invite

D. Cunningham — researcher profile on SciRah